PREDQ (Predictive Technology Group) Days Payable: 166.21 (As of Mar. 2021)


What is Predictive Technology Group Days Payable?

Predictive Technology Group PREDQ -90.00% Days Payable is 166.21 as of Mar. 2021.

Predictive Technology Group's average Accounts Payable for the three months ended in Mar. 2021 was $5.32 Mil. Predictive Technology Group's Cost of Goods Sold for the three months ended in Mar. 2021 was $2.92 Mil. Hence, Predictive Technology Group's Days Payable for the three months ended in Mar. 2021 was 166.21.

The historical rank and industry rank for Predictive Technology Group's Days Payable or its related term are showing as below:

PREDQ's Days Payable is not ranked *
in the Biotechnology industry.
Industry Median: 113.56
* Ranked among companies with meaningful Days Payable only.

Predictive Technology Group's Days Payable increased from Mar. 2020 (91.90) to Mar. 2021 (166.21). It may suggest that Predictive Technology Group delayed paying its suppliers.


Predictive Technology Group Days Payable Historical Data

* Premium members only.

The historical data trend for Predictive Technology Group's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Predictive Technology Group Days Payable Chart

Predictive Technology Group Annual Data
Trend Aug06 Aug07 Jun16 Jun17 Jun18 Jun19 Jun20
Days Payable
Get a 7-Day Free Trial 277.40 224.78 98.67 70.17 88.05

Predictive Technology Group Quarterly Data
Nov07 Feb08 May08 Jun16 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21
Days Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 91.90 133.06 145.79 198.05 166.21

PREDQ vs GLMD, RCAR, CKPT: Days Payable Comparison

For the Biotechnology subindustry, Predictive Technology Group's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Predictive Technology Group Days Payable vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Predictive Technology Group's Days Payable distribution charts can be found below:

* The bar in red indicates where Predictive Technology Group's Days Payable falls into.



Predictive Technology Group Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Predictive Technology Group's Days Payable for the fiscal year that ended in Jun. 2020 is calculated as

Days Payable (A: Jun. 2020 )
=Average Accounts Payable /Cost of Goods Sold*Days in Period
=( (Accounts Payable (A: Jun. 2019 ) + Accounts Payable (A: Jun. 2020 )) / count ) / Cost of Goods Sold (A: Jun. 2020 )*Days in Period
=( (4.943 + 4.988) / 2 ) / 20.585*365
=4.9655 / 20.585*365
=88.05

Predictive Technology Group's Days Payable for the quarter that ended in Mar. 2021 is calculated as:

Days Payable (Q: Mar. 2021 )
=Average Accounts Payable / Cost of Goods Sold*Days in Period
=( (Accounts Payable (Q: Dec. 2020 ) + Accounts Payable (Q: Mar. 2021 )) / count ) / Cost of Goods Sold (Q: Mar. 2021 )*Days in Period
=( (6.192 + 4.438) / 2 ) / 2.918*365 / 4
=5.315 / 2.918*365 / 4
=166.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Days Payable →
What does a Days Payable of 166.21 mean?
Predictive Technology Group (PREDQ) has a Days Payable of 166.21 as of Mar. 2021. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Predictive Technology Group and its competitors.
Is Predictive Technology Group's Days Payable too high?
Predictive Technology Group's current Days Payable is 166.21. The Biotechnology industry median Days Payable is 113.56. Predictive Technology Group's value of 166.21 is 46.4% above this industry median.
How does Predictive Technology Group's Days Payable compare to GLMD and RCAR?
Predictive Technology Group's Days Payable of 166.21 can be compared against companies in the Biotechnology industry. The industry median Days Payable is 113.56. Predictive Technology Group's value of 166.21 is 46.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 706 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Predictive Technology Group's current Days Payable of 166.21 is 46.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Predictive Technology Group and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Predictive Technology Group's current Days Payable is 166.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Predictive Technology Group stock overvalued right now?
Predictive Technology Group (PREDQ) has a current Days Payable of 166.21. The current Days Payable is 166.21 and 46.4% above the Biotechnology industry median of 113.56. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Predictive Technology Group (PREDQ), the current Days Payable is 166.21 as of Mar. 2021. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Predictive Technology Group Business Description

Address 2735 Parleys Way, Suite 205, Salt Lake City, UT, USA, 84109
Predictive Technology Group Inc (PRx) is a biotechnology company. It develops, commercializes, acquires and invests in technologies engaged in novel molecular diagnostic and therapeutic products in healthcare. The HCT/P segment offers minimally manipulated tissue products intended for homologous use, prepared utilizing proprietary extraction methods that reduce the loss of important scaffolding, growth factors and cytokines. The company's Diagnostics and Therapeutics segment uses data analytics for disease identification and subsequent therapeutic intervention through novel gene-based diagnostics, and companion therapeutics. It generates most of its revenues from HCT/Ps segment.